GlassScriptPhysician profile
James John Ignatz-Hoover
NPI 1679076442
$6,668.17
in general payments reported to CMS, 2019-2025
32 companies · $3,926 in 2025
The $3,926 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,332 · 2022: $253 · 2023: $222 · 2024: $935 · 2025: $3,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,943 · Food and Beverage: $1,496 · Consulting Fee: $475 · Travel and Lodging: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,943.00 |
| Food and Beverage | $1,496.21 |
| Consulting Fee | $475.00 |
| Travel and Lodging | $168.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,532.28 | 2021-2025 | |
| Pfizer INC. | $361.91 | 2022-2025 | |
| Legend Biotech USA INC. | $239.39 | 2025 | Carvykti |
| E.R. Squibb & Sons, L.L.C. | $201.72 | 2022-2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $154.08 | 2021-2025 | Fruzaqla, Ninlaro, Iclusig |
| Janssen Scientific Affairs, LLC | $150.00 | 2025 | Talvey |
| Incyte Corporation | $123.72 | 2021-2025 | Jakafi, Niktimvo, Pemazyre |
| Novartis Pharmaceuticals Corporation | $114.92 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.80 | 2022-2023 | Gilotrif |
| Eisai INC. | $62.65 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $55.82 | 2022-2024 | Zepzelca |
| Celgene Corporation | $51.43 | 2023-2024 | Reblozyl |
| Daiichi Sankyo INC. | $41.33 | 2024 | Enhertu |
| Merck Sharp & Dohme LLC | $39.00 | 2023-2024 | Keytruda, Welireg |
| Emd Serono, INC. | $38.21 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $36.66 | 2024 | Pyrukynd |
| Pharmacyclics LLC, An Abbvie Company | $35.66 | 2022-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $35.10 | 2024 | Imfinzi |
| Array Biopharma INC | $32.70 | 2022 | |
| Abbvie INC. | $32.43 | 2025 | |
| Alexion Pharmaceuticals, INC. | $31.54 | 2021-2023 | Ultomiris |
| Blueprint Medicines Corporation | $30.99 | 2025 | Ayvakit |
| Astellas Pharma US INC | $30.77 | 2024 | |
| Genmab U.S., INC. | $27.03 | 2023 | Epkinly |
| Rigel Pharmaceuticals, INC. | $24.23 | 2022 | |
| Morphosys, US INC. | $23.66 | 2022 | |
| Beigene USA, INC. | $23.38 | 2022 | |
| Sobi, INC | $22.02 | 2024 | |
| Genentech USA, INC. | $18.69 | 2023 | Tecentriq, Alecensa |
| Seagen INC. | $14.99 | 2022 | |
| Amgen INC. | $14.06 | 2025 | Kyprolis |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ignatz-Hoover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.